BioNTech’s ELCC 2026 Lung Cancer Data

BioNTech’s company press release detailing its ELCC 2026 lung cancer presentations outlines oral and poster updates spanning immunomodulators and antibody-drug conjugates across multiple lung cancer subtypes and lines of therapy. It highlights three programs—pumitamig (a PD‑L1×VEGF‑A bispecific immunomodulator), gotistobart (an anti‑CTLA‑4 candidate), and the HER3‑targeted ADC BNT326/YL202—and frames the readouts as preliminary, describing antitumor activity alongside safety/tolerability characterized as manageable or favorable in the release. The release also places the updates within an active late-stage clinical program, emphasizing ongoing pivotal and combination trials.

For pumitamig, the press release reports updated follow-up across three clinical trials conducted in China and characterizes the findings as “encouraging preliminary antitumor activity” with “manageable” safety/tolerability. The release lists the reported settings as: first-line (1L) extensive-stage small cell lung cancer (ES‑SCLC) with pumitamig in combination with chemotherapy; 1L advanced non-small cell lung cancer (NSCLC) with pumitamig as monotherapy (reported in both squamous and non-squamous disease); and EGFR‑mutant advanced/metastatic NSCLC with pumitamig combined with chemotherapy. The release describes these data as supporting the ongoing ROSETTA Lung‑01 and ROSETTA Lung‑02 programs, presented as part of the company’s broader late-stage lung cancer development strategy.

For gotistobart, the release attributes the update to the stage 1, dose-confirmation (non-pivotal) portion of the global Phase 3 PRESERVE‑003 trial in second-line or later (2L+) squamous NSCLC, described in patients who progressed after prior immunotherapy plus chemotherapy. In this stage 1 readout, the release reports an overall survival benefit versus standard-of-care chemotherapy in the non-pivotal, dose-confirmation portion of the study, described as a “54% reduction in the risk of death,” and characterizes the findings as “clinically meaningful” antitumor activity with a manageable safety profile. The company also notes that the pivotal stage of the Phase 3 trial is ongoing, placing the stage 1 report within its late-stage development program for this candidate. The comparison is presented as an interim update within an active Phase 3 framework.

The release also describes first clinical NSCLC data for the HER3-targeted ADC BNT326/YL202 from a China-based Phase 2 NSCLC cohort, summarizing the signal as antitumor activity with a “favorable safety profile.” Safety is characterized in broad terms in that summary wording (for example, as a “favorable safety profile”), without adverse-event category detail. Alongside this monotherapy disclosure, the release references planned and ongoing combination evaluations that include pumitamig in combination with an ADC, including a pumitamig plus BNT326/YL202 study, while keeping the description at the level of combination evaluation rather than mechanistic rationale. Across the portfolio, the company states it has 16 ongoing lung cancer trials, including four pivotal Phase 3 trials and five novel-novel combination trials, and uses the ELCC timing to contextualize these updates.